Sign in

NCT07205913Not yet recruiting

Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND

Source: ClinicalTrials.gov · Last updated 9 Mar 2026

Brief summary (registry, in English)

In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30. At the same time, the prevalence of type 2 diabetes continues to rise steadily. The burden of these diseases does not affect communities uniformly. While known factors such as diet, physical activity, and socioeconomic conditions play a role, studies have demonstrated the involvement of the gut microbiota in the development of metabolic disorders, particularly obesity and insulin resistance. However, this area remains largely unexplored in New Caledonia and the Pacific.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
270 (estimated)
First submitted
25 Sept 2025
Start date
15 Feb 2026
Primary completion date
15 Feb 2027
Lead sponsor
Institut Pasteur
NCT number
NCT07205913

What you commit to

  • Study type: Observational
  • Planned participants: 270
  • From 15 Feb 2026 to the primary completion date, 15 Feb 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy)
  • Organ transplantation and patients receiving immunosuppressive therapy

Other illness

  • Chronic or acute inflammatory bowel disease or infections
  • Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer
  • Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders
  • Severe renal failure and/or patients undergoing dialysis
  • Cardiovascular, endocrine, renal, or other chronic disease that may affect motility.

Other

  • All participants :
  • Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants
  • Preparation for colon cleansing within the last month
  • \< 3 bowel movements per week
  • Women who are pregnant or breastfeeding

Who the study is looking for

  • Aged between 18 and 60 years.
  • Ability to understand and provide informed consent.
  • Ability and willingness to meet the required schedule and study interventions.
  • Willingness to share their community belonging
  • Benefit from a social security system.
    • For obese and diabetic patients :
  • IMC ≥ 30 kg/m² with type 2 diabetes
  • Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or
  • Patients with HbA1c ≥ 6.5% (48 mmol/mol)
  • All stages of albuminuria For obese patients without type 2 diabetes
  • IMC ≥ 30 kg/m²
  • Weight stable for at least 2 months
  • Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 %
  • No treatment (diabetic or weight loss)
  • Match age (±5years), sex and self-reported community to the patients from the1 group.
    • For control group :
  • BMI between 18.5-24.9 kg/m²
  • Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups.
  • Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 %

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.